Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $49.96 and last traded at $47.33, with a volume of 134025 shares changing hands. The stock had previously closed at $49.93.
Gemini Therapeutics Stock Down 2.4 %
The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -47.90 and a beta of -0.12. The business has a 50-day moving average of $47.78 and a two-hundred day moving average of $41.52.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Momentum Trades for October With Ample Upside Ahead
- The Most Important Warren Buffett Stock for Investors: His Own
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
